Evoke Pharma (EVOK) Misses Q3 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Evoke Pharma Reports Third Quarter 2017 Results and Highlights
November 14, 2017 4:05 PM ESTAnnounced positive topline results from comparative exposure pharmacokinetic (PK) trial for Gimoti505(b)(2) New Drug Application (NDA) submission on track for Q1 2018 filingPartnered with the Patheon division of Thermo Fisher Scientific Inc. as a commercial manufacturing partner for Gimoti$10.4M in cash and extended estimated cash runway now through June 2018
SOLANA BEACH, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September... More
